Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

NYSE:PFE - Post Discussion

Pfizer Inc > U.S. FDA staff backs Pfizer's coronavirus vaccine
View:
Post by Humanist on Dec 08, 2020 9:27am

U.S. FDA staff backs Pfizer's coronavirus vaccine

U.S. FDA staff backs Pfizer's coronavirus vaccine
U.S. FDA staff backs Pfizer's coronavirus vaccine

Dec 8 (Reuters) - U.S. Food and Drug Administration (FDA) staff said on Tuesday that data on Pfizer Inc's coronavirus vaccine was in line with its guidance on emergency use authorization, raising hopes it could soon be available to Americans aged 16 and above.

The comments were made in documents released ahead of Thursday's meeting of outside experts to discuss whether the shot developed with German partner BioNTech SE should be authorized for emergency use. (https://bit.ly/3ov6eYr)

The FDA is expected to decide on whether to authorize the vaccine within days or weeks.

(Reporting by Manas Mishra in Bengaluru and Michael Erman in New York; Editing by David Clarke)

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities